Andrea Keane
Family · Seymour, INNPI 1720414915
Payments from drug & device makers
Across 265 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$906
- Otsuka America Pharmaceutical, Inc.$568
- Orexo US, Inc.$287
- Indivior Inc.$234
- Braeburn Inc.$214
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,26398%
- Education$682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $1,052 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $906 |
| Otsuka America Pharmaceutical, Inc. | 36 | $568 |
| Orexo US, Inc. | 22 | $287 |
| Indivior Inc. | 13 | $234 |
| Braeburn Inc. | 13 | $214 |
| Axsome Therapeutics, Inc. | 9 | $167 |
| Neurocrine Biosciences, Inc. | 7 | $152 |
| Vanda Pharmaceuticals Inc. | 6 | $133 |
| Gilead | 6 | $118 |
| Lundbeck LLC | 5 | $110 |
| Alkermes, Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| USWM, LLC | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Almatica Pharma LLC | 1 | $21 |
| Corium, LLC | 1 | $19 |
| GSK | 1 | $13 |
How this compares
$4,331 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 236 | $33,299 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $19,817 |
| RexultiBrexpiprazole | 11 | $15,811 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $11,452 |
| Lurasidone Hcl | 15 | $6,478 |
| Armodafinil | 14 | $2,232 |
| Buprenorphine Hcl | 33 | $1,798 |
| Ziprasidone Hcl | 11 | $1,133 |
| Gabapentin | 79 | $1,119 |
| Olanzapine OdtOlanzapine | 12 | $1,113 |
| Modafinil | 13 | $1,084 |
| Pindolol | 11 | $760 |
| Ondansetron Hcl | 28 | $581 |
| Quetiapine Fumarate | 38 | $525 |
| Fluvoxamine Maleate | 12 | $512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $39 | $35,097269 claims |
| Indivior Inc.Suboxone | $234 | $19,81733 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $568 | $15,81111 claims |
| Orexo US, Inc.Zubsolv | $287 | $11,45214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Seymour
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.